© 2022 Regional Cancer Care Associates. All rights reserved.
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer Read more
Phase I/II clinical study of mRNA-4359 Administered Alone or in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors. Read more
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Read more
A PHASE 1, FIRST-IN-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors Read more
A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that harbor the TP53-R175H Mutation Read more
Collection of Biological Specimen and Data from patients with malignancy treated at John Theurer Cancer Center and Hackensack University Medical Center Read more
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer Read more
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects With Advanced Solid Malignant Tumors Read more
Real World Outcomes with Amivantamab Monotherapy in Patients with non-Exon 20 Insertion Epidermal Growth Factor Receptor (EGFR)-mutated Non-small Cell Lung Cancer (NSCLC) Read more
